for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Onconova Therapeutics Inc

ONTX.OQ

Latest Trade

0.35USD

Change

0.06(+19.82%)

Volume

9,470,984

Today's Range

0.34

 - 

0.38

52 Week Range

0.10

 - 

4.72

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
0.29
Open
0.37
Volume
9,470,984
3M AVG Volume
136.83
Today's High
0.38
Today's Low
0.34
52 Week High
4.72
52 Week Low
0.10
Shares Out (MIL)
8.20
Market Cap (MIL)
2.87
Forward P/E
-0.13
Dividend (Yield %)
--

Latest Developments

More

Inceptua Medicines Access And Onconova Therapeutics Announce Pre-Approval Access Collaboration For Rigosertib In Some Countries Outside U.S.

Point72 Asset Management Reports 9.99% Passive Stake In Onconova Therapeutics

Onconova Therapeutics Will Offer Up To 16.9 Mln Of Co's Units - SEC Filing

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Onconova Therapeutics Inc

Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company operates through the identification and development of oncology therapeutics segment. It is focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agents designed to work against specific cellular pathways that are important to cancer cells. It has over three clinical-stage product candidates and various preclinical programs that target kinases, cellular metabolism or cell division in preclinical development. The Company's lead product candidate, rigosertib, is being tested in both intravenous (IV) and oral formulations as a single agent, and the oral formulation is also being tested in combination with azacitidine, in clinical trials for patients with myelodysplastic syndromes (MDS), and related cancers. Its other product candidates include Briciclib and Recilisib.

Industry

Biotechnology & Drugs

Contact Info

375 Pheasant Run

+1.267.7593681

http://www.onconova.com/

Executive Leadership

Michael M. B Hoffman

Chairman of the Board

Steven M. Fruchtman

President, Chief Executive Officer, Director

Mark Guerin

Chief Financial Officer

Manoj Maniar

Senior Vice President - Product Development

Abraham N. Oler

Vice President, Corporate Development and General Counsel

Key Stats

2.25 mean rating - 4 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-0.356

2017

-0.179

2018

-4.990

2019(E)

-2.760
Price To Earnings (TTM)
--
Price To Sales (TTM)
1.30
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
-336.17
Return on Equity (TTM)
-146.92

Latest News

Latest News

BRIEF-Oleg Nodelman Reports 9.99 Pct Passive Stake In Onconova Therapeutics As Of April 27, 2018

* OLEG NODELMAN REPORTS 9.99 PERCENT PASSIVE STAKE IN ONCONOVA THERAPEUTICS INC, AS OF APRIL 27, 2018 - SEC FILING Source text: (https://bit.ly/2KJY3o0) Further company coverage:

BRIEF-Onconova Therapeutics Announces Pricing Of $25 Mln Upsized Underwritten Public Offering

* ONCONOVA THERAPEUTICS ANNOUNCES PRICING OF $25.0 MILLION UPSIZED UNDERWRITTEN PUBLIC OFFERING

BRIEF-Onconova Presents Data On Dual Inhibitor Of Cdk4/6 + Ark5 At American Association For Cancer Research 2018 Annual Meeting

* ONCONOVA PRESENTS DATA ON DUAL INHIBITOR OF CDK4/6 + ARK5 AT AMERICAN ASSOCIATION FOR CANCER RESEARCH 2018 ANNUAL MEETING

BRIEF-Onconova Therapeutics Says Offering Up To 18.5 Mln Units Of Common Stock, Warrants

* ONCONOVA THERAPEUTICS - OFFERING UP TO 18.5 MILLION UNITS (UNIT CONSISTING OF ONE SHARE OF COMMON STOCK AND ONE WARRANT) Source text (https://bit.ly/2J0SqAg) Further company coverage:

BRIEF-Onconova Therapeutics Reports Full-Year 2017 Results

* ONCONOVA THERAPEUTICS, INC. REPORTS BUSINESS HIGHLIGHTS AND FULL YEAR 2017 FINANCIAL RESULTS

BRIEF-Onconova Therapeutics Announces License Agreement With Pint Pharma To Commercialize Rigosertib

* ONCONOVA THERAPEUTICS ANNOUNCES LICENSE AGREEMENT WITH PINT PHARMA TO COMMERCIALIZE RIGOSERTIB FOR TREATMENT OF MYELODYSPLASTIC SYNDROMES IN LATIN AMERICA

BRIEF-683 Capital Management Reports 21.8 Pct Stake In Onconova Therapeutics

* 683 CAPITAL MANAGEMENT LLC REPORTS 21.8 PERCENT STAKE IN ONCONOVA THERAPEUTICS INC AS OF FEB 8 - SEC FILING

BRIEF-Onconova Says Moving Forward With Pivotal Late-Stage Trial

* ONCONOVA MOVING FORWARD WITH PHASE 3 INSPIRE PIVOTAL TRIAL WITH INCREASED SAMPLE SIZE FOLLOWING PROMISING INTERIM ANALYSIS

BRIEF-Onconova Therapeutics Says Entered Into Cooperative Research And Development Agreement With NCI

* ONCONOVA THERAPEUTICS SAYS ENTERED INTO COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT WITH NATIONAL CANCER INSTITUTE

BRIEF-Onconova Therapeutics Announces License And Collaborative Development Agreement With Hanx Biopharma

* ONCONOVA THERAPEUTICS ANNOUNCES LICENSE AND COLLABORATIVE DEVELOPMENT AGREEMENT WITH HANX BIOPHARMACEUTICALS FOR ON 123300, A DUAL INHIBITOR OF CDK4/6 + ARK5

BRIEF-Onconova Therapeutics files for mixed shelf offering of upto $84.5 mln

* Onconova Therapeutics Inc files for mixed shelf offering of upto $84.5 million- SEC filing Source text: (http://bit.ly/2AiGwl1) Further company coverage:

BRIEF-Onconova Therapeutics announces data on improved formulation of Rigosertib and next-generation CDK4/6 inhibitor

* Onconova Therapeutics announces data on improved formulation of Rigosertib and next-generation CDK4/6 inhibitor at 2017 American Association Of Pharmaceutical Scientists annual meeting Source text for Eikon: Further company coverage:

BRIEF-Onconova Therapeutics prices public offering

* Onconova Therapeutics announces pricing of public offering of common stock

BRIEF-Onconova Therapeutics reports Q3 revenue $100,000

* Onconova Therapeutics, Inc. reports business highlights and third quarter 2017 financial results

BRIEF-Cellectar Biosciences enters into strategic collaboration with Onconova Therapeutics

* Cellectar Biosciences enters into strategic collaboration with Onconova Therapeutics to develop new phospholipid drug conjugates

BRIEF-Onconova Therapeutics reports qtrly net loss per share of $0.29

* Onconova Therapeutics, Inc. reports recent business highlights and second quarter 2017 financial results

BRIEF-Onconova Therapeutics Q1 loss per share $1.23

* Onconova therapeutics, inc. Reports recent business highlights and first quarter 2017 financial results

BRIEF-Sabby Management LLC reports 7.61 percent passive stake in Onconova Therapeutics

* Sabby Management LLC reports 7.61 percent passive stake in Onconova Therapeutics Inc as of April 21 - sec filing Source text : http://bit.ly/2oQ05LT Further company coverage:

BRIEF-ONCONOVA THERAPEUTICS PRICES PUBLIC OFFERING OF COMMON STOCK AT $2.10/SHARE

* ONCONOVA THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

BRIEF-Onconova Therapeutics says entered market issuance sales agreement with FBR Capital

* Onconova Therapeutics- on dec. 5, 2016, co entered into at market issuance sales agreement with FBR capital to create an at--market equity program

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up